Alpha 1 Lung Disease Market, By Disease Type (Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis, Bronchiectasis, and Others), By Treatment Type, By Route of Administration, By Distribution Channel, By Region

Description

The Alpha 1 Lung Disease Market size is expected to reach US$ 16.78 billion by 2030, from US$ 4.99 billion in 2023, at a CAGR of 18.9% during the forecast period.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 4.99 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	18.90%	2030 Value Projection:	US$ 16.78 Bn

Figure 1. Alpha 1 Lung Disease Market Share (%), by Region, 2023

Alpha 1 Lung Disease is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency of alpha-1 antitrypsin (AAT), a protein that helps protect the lungs from damage. This condition leads to the development of chronic obstructive pulmonary disease (COPD) and liver disease.

The global Alpha 1 Lung Disease market is driven by the increasing prevalence of the disease, growing awareness among healthcare professionals, and advancements in diagnostic techniques. According to the Alpha-1 Foundation, it is estimated that around 100,000 individuals in the U.S. and Europe have been diagnosed with Alpha 1 Lung Disease. However, the actual number of affected individuals is believed to be much higher.

Market Dynamics:

The market for Alpha 1 Lung Disease is primarily driven by the rising prevalence of the disease. As more individuals are being diagnosed with Alpha 1 Lung Disease, the demand for effective treatment options is increasing. This has led to a surge in research and development activities by key players in the market.

However, there are certain factors that restrain the growth of the market. Limited awareness about the disease among the general population and healthcare professionals hinders early diagnosis and treatment. Additionally, the high cost of treatment and lack of reimbursement policies in some regions pose challenges to market growth.

Despite these challenges, the market presents several opportunities for growth. Technological advancements in diagnostic techniques, such as genetic testing, are expected to improve early detection rates. Moreover, the development of novel therapies and targeted drugs holds promise for the treatment of Alpha 1 Lung Disease.

For instance, in June 2022, U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the Center within the U.S. Food and Drug Administration (FDA) are pleased to announce their partnership with the Critical Path Institute (C-Path), a non-profit organization to initiate planning for a consortium aimed at developing tools appropriate for use in clinical development programs for alpha-1 antitrypsin deficiency (AATD), a rare disease causing progressive destruction of lung tissue leading to premature mortality or need for lung transplant.

Key Features of the Study:

This report provides an in-depth analysis of the global Alpha 1 Lung Disease market, including market size (US$ Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period (2023-2030)
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
The key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited., CSL Behring, Vertex Pharmaceuticals Incorporated, Amgen Inc., Sanofi, GSK plc, Gilead Sciences, Inc., AbbVie Inc., and Regeneron Pharmaceuticals Inc.
Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
The global Alpha 1 Lung Disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha 1 Lung Disease market

Alpha 1 Lung Disease Market Segmentation:

By Disease Type
- Alpha-1 Antitrypsin Deficiency
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Fibrosis
- Bronchiectasis
- Others
By Treatment Type
- Augmentation Therapy
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
- Lung Transplantation
- Others
By Route of Administration
- Injectable
- Oral
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
Top Companies in the Alpha 1 Lung Disease Market
- AstraZeneca
- Boehringer Ingelheim International GmbH
- F.Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.,
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company Limited.
- CSL Behring
- Vertex Pharmaceuticals Incorporated
- Amgen Inc.
- Sanofi
- GSK plc
- Gilead Sciences, Inc.
- AbbVie Inc.
- Regeneron Pharmaceuticals Inc.

Product Code: CMI6188

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Alpha 1 Lung Disease, By Disease Type
- Market Alpha 1 Lung Disease, By Treatment Type
- Market Alpha 1 Lung Disease, By Route of Administration
- Market Alpha 1 Lung Disease, By Distribution Channel
- Market Alpha 1 Lung Disease, By Region
Coherent Opportunity Map (COaM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Rising Prevalence of COPD Globally
Increasing Diagnosis Rates
New Product Launches
Strong Pipeline of Drugs
Restraints
Limited awareness about the disease among the general population
Opportunities
Technological advancements in diagnostic techniques
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Alpha 1 Lung Disease Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Alpha 1 Lung Disease Market, By Disease Type, 2023-2030, (US$ Bn)

Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019 - 2030
Segment Trends
Alpha-1 Antitrypsin Deficiency
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Chronic Obstructive Pulmonary Disease (COPD)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Pulmonary Fibrosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Bronchiectasis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Alpha 1 Lung Disease Market, By Treatment Type, 2023-2030, (US$ Bn)

Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019 - 2030
Segment Trends
Augmentation Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
Bronchodilators
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
Corticosteroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
Oxygen Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
Lung Transplantation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)

7. Alpha 1 Lung Disease Market, By Route of Administration, 2023-2030, (US$ Bn)

Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019 - 2030
Segment Trends
Injectable
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)

8. Alpha 1 Lung Disease Market, By Distribution Channel, 2023-2030, (US$ Bn)

Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019 - 2030
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)

9. Alpha 1 Lung Disease Market, By Region, 2023-2030, (US$ Bn)

Introduction
Market Share Analysis, By Country, 2023 and 2030 (%)
Y-o-Y Growth Analysis, For Country 2019-2030
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030,(US$ Bn)
South Africa
North Africa
Central Africa

10. Competitive Landscape

AstraZeneca
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Boehringer Ingelheim International GmbH
Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc.
Merck & Co., Inc.
Bristol-Myers Squibb
Takeda Pharmaceutical Company Limited.
CSL Behring
Vertex Pharmaceuticals Incorporated
Amgen Inc.
Sanofi
GSK plc
Gilead Sciences, Inc.
AbbVie Inc.
Regeneron Pharmaceuticals Inc.
Analyst Views

11. Section

Research Methodology
About us